Donor Factors and Platelet Degranulation Drive Whole Blood Antifibrinolytic Variability

The Biological Evolution of Stored Whole Blood in Trauma Resuscitation

Hemorrhage remains the primary preventable cause of death following traumatic injury, necessitating rapid and effective hemostatic resuscitation [1, 2]. While conventional therapy utilizes a balanced ratio of red cells, plasma, and platelets, there is a resurgent interest in cold-stored whole blood because it maintains a physiological concentration of cells and clotting factors [3, 4]. Recent meta-analyses of civilian trauma data indicate that whole blood is associated with a significant reduction in 24-hour mortality (OR 0.73; 95% CI, 0.57 to 0.93) and a decrease in total transfusion requirements by a mean of 2.66 units [4, 1]. However, blood components undergo complex biochemical and structural changes during refrigeration, a process known as a storage lesion (the progressive degradation of blood cells and proteins that can trigger inflammatory responses or impair hemostasis in the recipient) [5]. A new study investigates how donor-specific factors and the platelet storage lesion (the release of intracellular markers during cell degradation) drive variability in the antifibrinolytic profile of stored units [6].

Quantifying the Paradox of Fibrinolytic Susceptibility

Whole blood transfusion is increasingly used in trauma resuscitation as clinicians seek to replicate physiological hemostasis more closely than is possible with component therapy. However, the efficacy of this approach is complicated by the biochemical evolution of the blood during refrigeration. The researchers found that stored whole blood units demonstrate increasing susceptibility to tissue plasminogen activator-mediated fibrinolysis (the enzymatic breakdown of fibrin clots) over time. This vulnerability is clinically significant because it occurs despite paradoxical increases in plasminogen activator inhibitor-1 (PAI-1) activity during storage. Under normal physiological conditions, PAI-1 serves as the primary inhibitor of clot breakdown, yet its accumulation in stored units does not appear to prevent the overall trend toward clot instability.

To characterize the drivers of this variability, the study analyzed plasma from 28 whole blood units generated via serial centrifugation (a method of spinning blood at sequential speeds to isolate the liquid plasma from cellular elements). These samples were evaluated at two critical time points: early storage on Days 1 to 3 and late storage on Day 21. The researchers employed a modified enzyme-linked immunosorbent assay (a targeted antibody-based detection method) designed to only capture active PAI-1, ensuring that the measurements reflected functional protein levels rather than degraded or inactive forms. Statistical analysis of the resulting data was performed using two-tailed t-tests with significance set at p < 0.05, providing a rigorous framework to identify how donor-specific factors and storage duration influence the antifibrinolytic potential of the blood.

Donor-Dependent Heterogeneity in Antifibrinolytic Activity

The analysis of the 28 whole blood units revealed that the biochemical profile of the blood is not uniform across the donor population. Instead, the study identified two distinct donor pools: one with high PAI-1 activity and one with low PAI-1 activity. This stratification is clinically relevant because PAI-1 serves as the primary endogenous brake on clot dissolution. The existence of these two groups suggests that the baseline capacity of a blood unit to maintain clot stability is inherently variable from the moment of collection.

This divergence in antifibrinolytic capacity is an early onset phenomenon rather than a consequence of prolonged refrigeration. The researchers found that the whole blood units stratified into distinct high and low PAI-1 activity cohorts at early storage time points, specifically during the initial window of Days 1 to 3. These findings indicate that stored whole blood demonstrates early, donor-dependent heterogeneity in antifibrinolytic potential, reflected by these distinct PAI-1 activity cohorts at the time of donation. For the practicing physician, this suggests that the initial hemostatic efficacy of a whole blood unit is heavily influenced by donor-specific biological factors present well before the development of traditional storage lesions, potentially explaining why some massively transfused patients achieve hemostasis faster than others.

The Role of Platelet Storage Lesions and Endothelial Markers

To determine the biological drivers of the observed variability in antifibrinolytic capacity, the researchers investigated whether PAI-1 activity in whole blood donors primarily comes from the endothelium (the inner lining of blood vessels) or from platelet degranulation (the release of clotting factors from platelets). The study utilized two specific biomarkers to differentiate these sources: soluble CD40 ligand (sCD40L), which was quantified as a platelet-derived marker of activation and cell death, and total von Willebrand Factor antigen levels, which served as a highly specific marker for endothelial degranulation. By measuring these proteins alongside active PAI-1, the authors sought to map the relationship between donor-specific endothelial factors and the progressive cellular degradation that occurs during refrigeration.

The longitudinal data revealed that PAI-1 activity increased overall during the storage period, a trend that coincided with the development of a significant platelet storage lesion. Specifically, sCD40L levels increased approximately 4-fold during storage, indicating substantial platelet breakdown and the release of intracellular contents into the plasma. However, the initial stratification of units into high and low activity groups was driven by both cellular sources. At early time points, both sCD40L levels and von Willebrand Factor antigen levels were significantly higher in the high PAI-1 cohort. These findings suggest that the variability in PAI-1 activity has a mixed source, stemming from both endothelial and platelet factors that differ from donor to donor.

For the clinician, these results clarify that the hemostatic potential of a whole blood unit is not a static value but a dynamic product of the donor's baseline physiology and the subsequent storage process. Because both endothelial and platelet-derived markers were elevated in the high PAI-1 group at the time of donation, the antifibrinolytic potential of stored whole blood is likely determined by a combination of the donor's pre-existing endothelial state and the severity of the platelet storage lesion. This mixed biological origin explains why some units maintain higher resistance to clot breakdown than others, a factor that could ultimately influence the success of resuscitation in patients with trauma-induced coagulopathy.

References

1. Ibrahim W, Monge KM, Menzel J, et al. Whole-Blood vs Component Therapy in Adult Trauma: An Updated Systematic Review and Meta-Analysis.. JAMA surgery. 2026. doi:10.1001/jamasurg.2026.0197

2. Souza L, Ribeir PFM, Santos ROC, Moreira RFDF, Lima PMA, Araújo LCN. Damage Control Resuscitation: Evidence-based Systematic Review for Treating Traumatized Patients. Journal of Advances in Medicine and Medical Research. 2024. doi:10.9734/jammr/2024/v36i65477

3. García AF, Caicedo Y, Gempeler A, et al. Transfusion of modified whole blood versus blood components therapy in patients with severe trauma: Randomized controlled trial protocol (WEBSTER trial).. Injury. 2025. doi:10.1016/j.injury.2025.112173

4. Risha M, Alotaibi AM, Smith SA, et al. Does early transfusion of cold-stored whole blood reduce the need for component therapy in civilian trauma patients? A systematic review. Journal of Trauma and Acute Care Surgery. 2024. doi:10.1097/TA.0000000000004429

5. Borges J, Guedes C, Viotto CMBW. Major clinical findings of blood and blood component transfusion in polytrauma: a systematic review. MedNEXT Journal of Medical and Health Sciences. 2025. doi:10.54448/mdnt25201

6. Maginot ER, Barmettler NK, Gawargi FI, et al. Platelet storage lesion underlies changes in plasminogen activator inhibitor-1 activity in stored whole blood.. The journal of trauma and acute care surgery. 2026. doi:10.1097/TA.0000000000005012